Get started
Author

Bernard Doger de Spéville Uribe

Observed names: B. Doger De Speville Uribe, B. Doger de Speville Uribe, B.G. Doger Speville Uribe, Bernard Doger de Speville Uribe, Bernard Gaston Doger de Speville Uribe
OpenAlex ID: A5046669159
Efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, and pembrolizumab in patients with immune checkpoint inhibitor-naive unresectable or metastatic melanoma: Updated results from IOV-COM-202 cohort 1A.
2024 · Sajeve Samuel Thomas, Helen Gogas, et al. · Journal of Clinical Oncology · 26
PDF
Lurbinectedin Plus Pembrolizumab in Relapsed SCLC: The Phase I/II LUPER Study
2025 · Antonio Calles, Alejandro Navarro, et al. · Journal of Thoracic Oncology · 17
PDF
Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and combined with abemaciclib, in recurrent/advanced ER-positive endometrioid endometrial cancer: Results from the phase 1a/1b EMBER study
2024 · Kan Yonemori, Valentina Boni, et al. · Gynecologic Oncology · 11
PDF
Beamion BCGC-1: phase Ib/II trial of zongertinib for advanced HER2-positive breast or gastroesophageal cancers
2025 · Sara Hurvitz, Matteo Simonelli, et al. · Future Oncology · 5
PDF
AIPAC-003: A randomized, double-blind, placebo-controlled phase 3 trial testing eftilagimod alpha (soluble LAG-3) in patients with HER2-neg/low metastatic breast cancer receiving paclitaxel, following an open-label dose optimization.
2024 · Frederic Forget, Serafin Morales Murillo, et al. · Journal of Clinical Oncology · 5
266P MEN1611, a PI3K inhibitor, combined with trastuzumab (T) ± fulvestrant (F) for HER2+/PIK3CA mutant (mut) advanced or metastatic (a/m) breast cancer (BC): Safety and efficacy results from the ongoing phase Ib study (B-PRECISE-01)
2021 · M. Piccart, M. Ruiz Borrego, et al. · Annals of Oncology · 4
Efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, and pembrolizumab in patients with immune checkpoint inhibitor–naive unresectable or metastatic melanoma: updated results from IOV-COM-202 Cohort 1A
2025 · H. Gogas, A.J. Furness, et al. · EJC Skin Cancer · 3
PDF
Abstract CT110: Safety and anti-tumor activity of a novel Treg depleter RG6292, as a single agent and in combination with atezolizumab in patients with solid tumors
2023 · Valentina Gambardella, Michael Ong, et al. · Cancer Research · 3
Abstract PD18-05: MEN1611, a PI3K inhibitor, combined with trastuzumab ± fulvestrant for HER2+/PIK3CA mutant advanced or metastatic breast cancer: updated safety and efficacy results from the ongoing phase 1b study (B-PRECISE-01)
2023 · Martine Piccart, Audrey Hennequin, et al. · Cancer Research · 3
Abstract CT235: A Phase 2, multicenter study of autologous tumor infiltrating lymphocytes (TIL, LN 144/LN-145/LN-145-S1) in patients with solid tumors
2021 · Scott Gettinger, Harriet Kluger, et al. · Cancer Research · 1
Imlunestrant, an oral selective estrogen receptor degrader (SERD), as monotherapy and in combination with abemaciclib, in endometrioid endometrial cancer (EEC): Results from the EMBER phase 1a/1b study.
2024 · Kan Yonemori, Kalyan Banda, et al. · Journal of Clinical Oncology
Prospective and external validation of an objective performance status (OPS) in patients with metastatic solid malignancies using wearable accelerometry.
2024 · Christopher Manz, Eva Ruiz-Hispán, et al. · Journal of Clinical Oncology
PDF
Abstract PO1-26-02: Enfortumab vedotin (EV): Correlation of estrogen receptor status and Nectin-4 expression with single agent efficacy in breast XPDX models
2024 · Crystal Moreno, Johnnie Flores, et al. · Cancer Research
486P Bioavailability and activity of oncolytic virus TG6002 after intravenous administration in patients with advanced gastrointestinal carcinomas
2021 · P.A. Cassier, K. Bendjama, et al. · Annals of Oncology
PDF
P48.06 Lurbinectedin in Combination with Pembrolizumab for Patients with Relapsed Small Cell Lung Cancer. LUPER Clinical Trial
2021 · M.J. De Miguel Luken, B.G. Doger Speville Uribe, et al. · Journal of Thoracic Oncology
PDF
Works count: 15
Citation count: 78
H-index: 5
I10-index: 3
Year
Topic
Type